This study shows #SARSCoV2 upregulates #CD147, driving extended infection and immune imbalance; #Meplazumab blocks CD147–spike interaction, restores immune balance, and mitigates severe #COVID19, highlighting CD147 as a therapeutic target.

#OpenAccess #STTT: doi.org/10.1038/s413...

#SARSCoV2 triggers AHR‑mediated #CD147 up‑regulation, reduces ACE2, and drives immune imbalance through #M2macrophage signaling, while #Meplazumab disrupts CD147‑spike binding, restores immune balance, and mitigates severe #COVID19.

#OpenAccess in #STTT: doi.org/10.1038/s413...

A phase 3 #ClinicalTrial evaluating efficacy of #Meplazumab, a humanized CD147 antibody, revealed that it reduces mortality and enhances clinical benefits with a good safety profile in severe #COVID19 patients.

#OpenAccess: doi.org/10.1038/s413...

Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial

This phase 3 trial shows that the #humanized #CD147 antibody #meplazumab significantly lowered 14, 28, and 56-day mortality, rapidly reduced #viralload, and improved multiple clinical outcomes in severe #COVID19 patients. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...